Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Cancer: Breakthrough Pain × Morphine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 19 Pain 17 Cancer Pain 16 Pain, Postoperative 9 Chronic Pain 7 Agnosia 5 Colonic Neoplasms 4 Breast Neoplasms 4 Neoplasm Metastasis 3 Multiple Myeloma 3 Mucositis 3 Lymphoma, Follicular 3 Lymphoma 3 Lung Neoplasms 3 Leukemia, Myeloid, Acute 3 Leukemia, Biphenotypic, Acute 3 Leukemia 3 Colorectal Neoplasms 3 Wounds and Injuries 2 Waldenstrom Macroglobulinemia 2 Thrombocythemia, Essential 2 Supratentorial Neoplasms 2 Sezary Syndrome 2 Primary Myelofibrosis 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Precancerous Conditions 2 Polycythemia Vera 2 Pdgfra-Associated Chronic Eosinophilic Leukemia 2 Pancreatic Neoplasms 2

Interventions

Morphine 1 Ketamine 1 Chitosan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02591017 2018-11-13

ONKEMI

University Hospital, Basel, Switzerland

Phase 3 Terminated

Cancer: Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon ⚡